The use of Yttrium-90 Ibritumomab Tiuxetan ((90)Y-IT) as a consolidation therapy in high-risk patients with diffuse large B-cell lymphoma ineligible for autologous stem-cell transp...

por Jurczak, Wojciech, Kisiel, Elżbieta, Sawczuk-Chabin, Joanna, Centkowski, Piotr, Knopińska-Posłuszny, Wanda, Khan, Omeir
Publicado 2015